ReviewPharmaceutics2020
Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals.
Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 90 citations in OpenAlex.
- m6A-Targeted Cancer Therapy: Molecular Targets, Inhibitors, and Nanodelivery Strategies.International journal of nanomedicine · 2026Review
- Microglia-Targeted Nanotherapeutics in Major Depressive Disorder: An Integrative Perspective on Neuroinflammation and Drug Delivery.Pharmaceutics · 2025Review
- Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study.International journal of molecular sciences · 2025Article
- Lipid-based nanocarriers in combination chemotherapy: a promising strategy for advanced skin cancer management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Delivery strategies to improve the pharmacological efficacy of NRF2 modulators: a review.RSC medicinal chemistry · 2025Review
- Development and evaluation of the rivaroxaban loaded nanostructured lipid carriers for improved oral bioavailability and safety.Scientific reports · 2025Article
- Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.Current pharmaceutical design · 2025Review
- The Know-how of Polymeric Nanocarrier Based Vaginal Drug Delivery System: Pitfalls, Challenges and Trends.Pharmaceutical nanotechnology · 2025Review
- Current status and trends in small nucleic acid drug development: Leading the future.Acta pharmaceutica Sinica. B · 2024Review
- Co-delivery of paclitaxel and curcumin loaded solid lipid nanoparticles for improved targeting of lung cancer:Heliyon · 2024Article
- The Optimization Design of Macrophage Membrane Camouflaging Liposomes for Alleviating Ischemic Stroke Injury through Intranasal Delivery.International journal of molecular sciences · 2024Article
- Targeted Nano-Based Systems for the Anti-Obesity Agent's Delivery.Advances in experimental medicine and biology · 2024Review
- Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application.Drug delivery · 2023Review
- A detailed insight of the tumor targeting using nanocarrier drug delivery system.Drug delivery · 2023Review
- Article
- Production and therapeutic use of astaxanthin in the nanotechnology era.Pharmacological reports : PR · 2023Review
- Challenges and Strategies to Enhance the Systemic Absorption of Inhaled Peptides and Proteins.Pharmaceutical research · 2023Review
- Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson's disease: mechanisms and therapeutic implications.Journal of neurology · 2023Review
- Formation Optimization, Characterization and Antioxidant Activity of Auricularia auricula-judae Polysaccharide Nanoparticles Obtained via Antisolvent PrecipitationMolecules (Basel, Switzerland) · 2022Article
- Carnosic Acid Encapsulated in Albumin Nanoparticles Induces Apoptosis in Breast and Colorectal Cancer Cells.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
Abstract
During the past two decades, the clinical use of biopharmaceutical products has markedly increased because of their obvious advantages over conventional small-molecule drug products. These advantages include better specificity, potency, targeting abilities, and reduced side effects. Despite the substantial clinical and commercial success, the macromolecular structure and intrinsic instability of biopharmaceuticals make their formulation and administration challenging and render parenteral delivery as the only viable option in most cases. The use of nanocarriers for efficient delivery of biopharmaceuticals is essential due to their practical benefits such as protecting from degradation in a hostile physiological environment, enhancing plasma half-life and retention time, facilitating absorption through the epithelium, providing site-specific delivery, and improving access to intracellular targets. In the current review, we highlight the clinical and commercial success of biopharmaceuticals and the overall applications and potential of nanocarriers in biopharmaceuticals delivery. Effective applications of nanocarriers for biopharmaceuticals delivery via invasive and noninvasive routes (oral, pulmonary, nasal, and skin) are presented here. The presented data undoubtedly demonstrate the great potential of combining nanocarriers with biopharmaceuticals to improve healthcare products in the future clinical landscape. In conclusion, nanocarriers are promising delivery tool for the hormones, cytokines, nucleic acids, vaccines, antibodies, enzymes, and gene- and cell-based therapeutics for the treatment of multiple pathological conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.